ESR1 ligand-binding domain mutations in hormone-resistant breast cancer

被引：0
|
作者：
Weiyi Toy
Yang Shen
Helen Won
Bradley Green
Rita A Sakr
Marie Will
Zhiqiang Li
Kinisha Gala
Sean Fanning
Tari A King
Clifford Hudis
David Chen
Tetiana Taran
Gabriel Hortobagyi
Geoffrey Greene
Michael Berger
José Baselga
Sarat Chandarlapaty
机构：
[1] Human Oncology and Pathogenesis Program,Ben May Department of Cancer Research
[2] Memorial Sloan-Kettering Cancer Center (MSKCC),Department of Surgery
[3] Toyota Technological Institute at Chicago,Solid Tumor Division, Department of Medicine
[4] University of Chicago,Department of Breast Medical Oncology
[5] Breast Service,Department of Pathology
[6] MSKCC,undefined
[7] Weill Cornell Medical College,undefined
[8] Breast Cancer Medicine Service,undefined
[9] MSKCC,undefined
[10] Novartis Pharmaceuticals Corporation,undefined
[11] MD Anderson Cancer Center,undefined
[12] MSKCC,undefined
来源：
Nature Genetics | 2013年 / 45卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Sarat Chandarlapaty and colleagues report the identification of mutations in the ESR1 gene affecting the ligand-binding domain of the encoded estrogen receptor in 20% of metastatic hormone-resistant breast cancers. They determine that the mutant receptor has a hormone-independent active state that likely promotes resistance to estrogen-depriving therapies.
引用
收藏
页码：1439 / 1445
页数：6
相关论文
共 50 条
  • [21] ESR1 mutations in metastatic lobular breast cancer patients
    Christine Desmedt
    Julien Pingitore
    Françoise Rothé
    Caterina Marchio
    Florian Clatot
    Ghizlane Rouas
    François Richard
    François Bertucci
    Odette Mariani
    Christine Galant
    Charlotte Fribbens
    Ben O’Leary
    Gert van den Eynden
    Roberto Salgado
    Nicholas C. Turner
    Martine Piccart
    Anne Vincent-Salomon
    Giancarlo Pruneri
    Denis Larsimont
    Christos Sotiriou
    npj Breast Cancer, 5
  • [22] The Impact of ESR1 Mutations on the Treatment of Metastatic Breast Cancer
    Sasha M. Pejerrey
    Derek Dustin
    Jin-Ah Kim
    Guowei Gu
    Yassine Rechoum
    Suzanne A. W. Fuqua
    Hormones and Cancer, 2018, 9 : 215 - 228
  • [23] ESR1 mutations in metastatic lobular breast cancer patients
    Desmedt, Christine
    Pingitore, Julien
    Rothe, Francoise
    Marchio, Caterina
    Clatot, Florian
    Rouas, Ghizlane
    Richard, Francois
    Bertucci, Francois
    Mariani, Odette
    Galant, Christine
    Fribbens, Charlotte
    O'Leary, Ben
    van den Eynden, Gert
    Salgado, Roberto
    Turner, Nicholas C.
    Piccart, Martine
    Vincent-Salomon, Anne
    Pruneri, Giancarlo
    Larsimont, Denis
    Sotiriou, Christos
    NPJ BREAST CANCER, 2019, 5 (1)
  • [24] ESR1 mutations, ESR1 fusions and co-occurring alterations assessed in breast cancer tumors
    Tan, A.
    Feldman, R.
    Pohlmann, P.
    Lynce, F.
    Swain, S.
    Nunes, M. R.
    Gatalica, Z.
    Ghazalpour, A.
    Swensen, J.
    Vidal, G.
    Obeid, E.
    Vacirca, J.
    Isaacs, C.
    Schwartzberg, L.
    CANCER RESEARCH, 2017, 77
  • [25] Targeted degradation of activating estrogen receptor α ligand-binding domain mutations in human breast cancer
    Gonzalez, Thomas L.
    Hancock, Molly
    Sun, Siqi
    Gersch, Christina L.
    Larios, Jose M.
    David, Waddie
    Hu, Jiantao
    Hayes, Daniel F.
    Wang, Shaomeng
    Rae, James M.
    BREAST CANCER RESEARCH AND TREATMENT, 2020, 180 (03) : 611 - 622
  • [26] Targeted degradation of activating estrogen receptor α ligand-binding domain mutations in human breast cancer
    Thomas L. Gonzalez
    Molly Hancock
    Siqi Sun
    Christina L. Gersch
    Jose M. Larios
    Wadie David
    Jiantao Hu
    Daniel F. Hayes
    Shaomeng Wang
    James M. Rae
    Breast Cancer Research and Treatment, 2020, 180 : 611 - 622
  • [27] mTOR inhibition in hormone-resistant breast cancer
    Sharma, Sharan Prakash
    LANCET ONCOLOGY, 2012, 13 (06): : E239 - E239
  • [28] Clinical relevance of ESR1 circulating mutations detection in hormone receptor positive metastatic breast cancer
    Clatot, Florian
    Perdrix, Anne
    Sefrioui, David
    Sarafan-Vasseur, Nasrin
    Di Fiore, Frederic
    BULLETIN DU CANCER, 2018, 105 (01) : 46 - 54
  • [29] Mutual exclusivity of ESR1 and TP53 mutations in endocrine resistant metastatic breast cancer
    Li, Zheqi
    Spoelstra, Nicole S.
    Sikora, Matthew J.
    Sams, Sharon B.
    Elias, Anthony
    Richer, Jennifer K.
    Lee, Adrian V.
    Oesterreich, Steffi
    NPJ BREAST CANCER, 2022, 8 (01)
  • [30] ESR1 mutations—a mechanism for acquired endocrine resistance in breast cancer
    Rinath Jeselsohn
    Gilles Buchwalter
    Carmine De Angelis
    Myles Brown
    Rachel Schiff
    Nature Reviews Clinical Oncology, 2015, 12 : 573 - 583
12345